Department of Neurology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States of America.
Department of Neurosurgery, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States of America.
PLoS One. 2023 Jan 27;18(1):e0281040. doi: 10.1371/journal.pone.0281040. eCollection 2023.
This study sought to identify differences in cannabis use and perceptions about cannabis in mitigating seizure-related symptoms in patients with epilepsy, and to evaluate differences in these patterns between drug-resistant versus pharmacoresponsive epilepsy. A collection of self-report surveys completed by patients with epilepsy (n = 76) were used to retrospectively compare differences in those with drug-resistant versus pharmacoresponsive epilepsy regarding 1) proportion who used cannabis, 2) frequency of use, 3) method of use, and 4) reason for use. A Cochran-Armitage test for trend indicated that of patients who used cannabis, a higher proportion of patients in the drug-resistant group used more frequently than in the pharmacoresponsive group. Almost half (48%) of those in the drug-resistant group reported daily use compared to approximately a third (36%) of those in the pharmacoresponsive group. Additionally, no patient in either group reported that cannabis was harmful in relation to seizure-related symptoms. Results from this study highlight the need for epilepsy providers to formally assess patients' perceptions and use of non-prescribed cannabis to inform clinical care decisions, particularly in the drug-resistant epilepsy population.
本研究旨在确定大麻使用情况和对大麻的认知在减轻癫痫患者癫痫相关症状方面的差异，并评估耐药性与药物反应性癫痫之间这些模式的差异。本研究使用了一组由癫痫患者完成的自我报告调查，回顾性比较了耐药性与药物反应性癫痫患者在以下方面的差异：1）使用大麻的比例；2）使用频率；3）使用方法；4）使用原因。Cochran-Armitage 趋势检验表明，在使用大麻的患者中，耐药组中使用频率更高的患者比例高于药物反应性组。几乎一半（48%）的耐药组患者报告每天使用，而药物反应性组患者中约有三分之一（36%）报告每天使用。此外，两组中没有患者报告大麻对癫痫相关症状有害。本研究结果强调了癫痫治疗提供者需要正式评估患者对非处方大麻的认知和使用情况，以告知临床护理决策，特别是在耐药性癫痫患者群体中。
